Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With Ustekinumab | Zendy

Emmanuella Guenova | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interleukin 23 Expression in Pyoderma Gangrenosum and Targeted Therapy With Ustekinumab

Author(s) -

Emmanuella Guenova

Publication year - 2011

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archdermatol.2011.168

Subject(s) - ustekinumab , pyoderma gangrenosum , medicine , interleukin 23 , psoriasis , crohn's disease , pathogenesis , immunology , interleukin , inflammatory bowel disease , monoclonal , lesion , monoclonal antibody , disease , cytokine , pathology , antibody , tumor necrosis factor alpha , infliximab

Interleukin (IL)-23 is involved in the pathogenesis of the chronic inflammatory Crohn disease. Pyoderma gangrenosum (PG) is often associated with and can even be the first manifestation of this disease and has abundant neutrophilic infiltration. Because IL-23 plays a critical role in driving inflammation associated with IL-17 production and especially neutrophil recruitment, we suspect that PG might be driven by a pathogenetic mechanism similar to that of inflammatory bowel diseases or psoriasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research